A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors

International Journal of Clinical Practice

Volumn 64, Issue 9, 2010, Pages 1220-1227

  Malekzadeh, F ^a   Marshall, T ^b   Pourshams, A ^a   Gharravi, M ^a   Aslani, A ^a   Nateghi, A ^a   Rastegarpanah, M ^c   Khoshnia, M ^a   Semnani, S ^d   Salahi, R ^d   Thomas, G N ^b   Larijani, B ^e   Cheng, K K ^a   Malekzadeh, R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ATORVASTATIN PLUS ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; ATORVASTATIN; ENALAPRIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; IRAN; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PATIENT COMPLIANCE; POLYPILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENALAPRIL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PYRROLES; RISK FACTORS; TABLETS;

EID: 77954643491     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02412.x     Document Type: Article

References (38)

1. World Health Organization 2005. Preventing chronic diseases: a vital investment. WHO global report. http://www.who.int/chp/chronic-disease-report/en/ [Last Accessed 21st April 2009].
2. Asadi-Laria M, Sayyarib AA, Akbaric ME, Gray D. Public health improvement in Iran - lessons from the last 20 years. Public Health 2004 118 : 395 402.
3. Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? Arch Iran Med 2008 11 : 306 313.
4. Larijani B, Fakhrzadeh H, Mohaghegh M, Pourebrahim R, Akhlaghi MR. Burden of coronary heart disease on the Iranian oil industry (1999-2000). East Mediterr Health J 2003 : 9 : 904 910.
5. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Br Med J 1994 308 : 363 366.
6. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990 335 : 765 774.
7. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 : 1903 1913.
8. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. Br Med J 2002 324 : 1570 1576.
9. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003 326 : 1423 1426.
10. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 335 : 827 839.
11. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Inter Med 2002 136 : 161 172. (Pubitemid 34073943)
12. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003 326 : 1419.
13. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009 9 : 112 119.
14. Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor for polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 2004 3 : 675 681.
15. Clinical Trials Research Unit. The University of Auckland (online 2008) PILL Pilot: Programme to Improve Life and Longevity http://www.ctru.auckland.ac. nz/content/view/37/35/ ]. (Last accessed 5th February 2009).
16. Xavier D, Pais P, Sigamani A et al. Investigators The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. Nat Clin Pract Cardiovasc Med 2009 9 : 96 7.
17. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006 368 : 679 686.
18. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Inter Med 2005 143 : 593 599.
19. Reddy KS. The preventive polypill - much promise, insufficient evidence. N Engl J Med 2007 356 : 3.
20. Health System Profile Islamic Republic of Iran. Regional Health Systems Observatory, World Health Organization, 2009. [Last accessed 21st April 2009] http://gis.emro.who.int/HealthSystemObservatory/PDF/Iran/Full%20Profile.pdf.
21. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007 10 : 70 82. review.
22. Pourshams A, Saadatian-Elahi M, Nouraie M et al. Golestan cohort study of oesophageal cancer: feasibility and first results. Br J Cancer 2005 92 : 176 181.
23. Bahrami H, Sadatsafavi M, Pourshams A et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006 6 : 158.
24. Effect of a Polypill on middle-aged and elderly Iranians http://www.controlled-trials.com/ISRCTN43076122/ [Last accessed 15th January 2008].
25. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003 326 : 1427 1432.
26. The Indian Polycap Study (TIPS) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009 373 : 1341 1351. Published Online March 30, 2009. DOI:.
27. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989 321 : 129 135.
28. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 296 : 313 316.
29. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998 351 : 233 241.
30. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 351 : 1755 1762. (Pubitemid 28269185)
31. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001 357 : 89 95.
32. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 352 : 1293 1304.
33. Ogawa H, Nakayama M, Morimoto T et al. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. J Am Med Assoc 2008 300 : 2134 2141.
34. Belch J, MacCuish A, Campbell I et al. Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, and Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008 337 : a1840.
35. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003 21 : 707 716.
36. Ridker PM, Danielson E, Fonseca FAH, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 2207.
37. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
38. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 373 : 1849 1860.